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Abstract
Objective: Postoperative course and functional outcome were evaluated in patients who underwent lung volume reduction surgery
(LVRS) or in combination with valve replacement (VR), percutaneous transluminal coronary angioplasty (PTCA), placement of a stent,
or coronary artery bypass grafting (CABG). Methods: Patients with severe bronchial obstruction and hyperin¯ation due to pulmonary
emphysema were evaluated for lung volume reduction surgery. Cardiac disorders were screened by history and physical examination and
assessed by coronary angiography. Nine patients were accepted for LVRS in combination with an intervention for coronary artery disease
(CAD). In addition, three patients with valve disease and severe emphysema were accepted for valve replacement (two aortic-, one mitral
valve) only in combination with LVRS. Functional results over the ®rst 6 months were analysed. Results: Pulmonary function testing
demonstrates a signi®cant improvement in postoperative FEV1 in patients who underwent LVRS combined with an intervention for CAD.
This was re¯ected in reduction of overin¯ation (residual volume/total lung capacity (RV/TLC)), and improvement in the 12-min walking
distance and dyspnea. Median hospital stay was 15 days (10±33). One patient in the CAD group died due to pulmonary edema on day 2
postoperatively. One of the three patients who underwent valve replacement and LVRS died on day 14 postoperatively following intestinal
infarction. Both survivors improved in pulmonary function, dyspnea score and exercise capacity. Complications in all 12 patients included
pneumothorax (n  2), hematothorax (n  1) and urosepsis (n  1). Conclusion: Functional improvement after LVRS in patients with CAD
is equal to patients without CAD. Mortality in patients who underwent LVRS after PTCA or CABG was comparable to patients without
CAD. LVRS enables valve replacement in selected patients with severe emphysema otherwise inoperable. q 1999 Elsevier Science 1reland
Ltd. All rights reserved.
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1. Introduction
Lung volume reduction surgery (LVRS) for patients with
end-stage emphysema and severe hyperin¯ation results in
decreased dyspnea and improved pulmonary function [1,2].
Most of the patients with end-stage emphysema have a
history of smoking and are therefore at increased risk for
coronary artery disease (CAD). Previously, we demon-
strated that in 15% of patients qualifying for LVRS relevant
CAD is present despite any clinical signs for CAD increas-
ing the risk for perioperative complications [3]. In total 12
of 124 patients who underwent LVRS at our institution were
treated for both, cardiac disease and emphysema.
In this study we retrospectively evaluated the periopera-
tive complications and functional outcome of these 12
patients which were operated in combination with cardiac
interventions (PTCA, coronary stenting, CABG, valve
replacement (VR)).
2. Patients and methods
Until August 1998, 285 patients with severe emphysema
were evaluated for LVRS at the University of Zurich. Poten-
tial candidates were considered for this type of surgery
according to selection and exclusion criteria previously
published [2±4]. Brie¯y, the patient suffers from severe
chronic obstructive pulmonary disease (COPD) with a forced
expiratory volume in 1 second (FEV 1) ,35% predicted and
static lung volumes demonstrate hyperin¯ation
(RV . 200%, TLC . 130% predicted). Radiological signs
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of emphysema are present on conventional chest radiograph
and emphysema is con®rmed on a high resolution CT scan.
Exclusion criteria are age over 75 years, PaCO2 . 55 mmHg,
diffusing capacity for carbon oxide (CO) (singlebreath)
,20% predicted, bronchiectasis, acute bronchopulmonary
infection, neoplastic disease with life expectancy ,2 years,
psychiatric disturbance, previous Q-wave infarction and/or
congestive heart failure, mean pulmonary artery pressure
.35 mmHg. All patients were screened for cardiac disorders
by history and physical examination. Routine right heart
catheterization was not performed. As we demonstrated
in a previous study, only patients with hypercarbia had
elevated pulmonary artery pressures [5]. Nine patients who
were evaluated for LVRS did not ful®ll the study criteria
because of relevant, but asymptomatic CAD which was
con®rmed by coronary angiography. Signi®cant CAD was
de®ned as narrowing of one or more vessels by at least 70% or
of the left main coronary artery by at least 50%. These nine
patients underwent LVRS in combination with treatment for
CAD.
In addition, three patients with valvular heart disease and
severe emphysema, which were considered inoperable due
to their extremely limited pulmonary function, underwent
valve replacement in combination with LVRS.
2.1. Patients with CAD
Coronary angiography revealed relevant coronary artery
disease in nine patients (one female) with a median age of
66 (56±74) years. Three patients had three-vessel disease,
four two-vessel-, and two one-vessel disease. One patient
with predominantly unilateral diffuse emphysema under-
went unilateral lung volume reduction surgery on the right
side following coronary artery bypass grafting (£5) in one
session. LVRS was performed through the median sternot-
omy when the patient was still on bypass using ELC45
staplers (Ethicon, Endo-Surgery, Switzerland) buttressed
with bovine pericardium (Peri-Strips Drye, Biovascular
INC, Saint Paul MN). In the second patient LVRS was
performed bilaterally by video-endoscopic approach six
months after CABG (£4). The other patients underwent
PTCA (n  7) and/or placement of a stent (n  4) 4±6
weeks prior to bilateral thoracoscopic LVRS. The patients
received Ticlidw (Ticlopidin) 2 £ 250 mg/day and Aspirin
100 mg/day for 4 weeks. The medication was stopped 1
week prior to LVRS.
2.2. Patients with valve disease
All three patients (67±70 years) who underwent LVRS in
combination with replacement of the mitral or aortic valve
were initially not accepted for a cardiac surgical interven-
tion because of severe COPD with emphysema. The ratio-
nale for the combined treatment was to improve pulmonary
function postoperatively with the aim to faciliate weaning
from the respirator [6]. Bilateral LVRS was performed in
one patient immediately after aortic valve replacement
through the median sternotomy. In the other two patients
LVRS was postponed because of intraoperative complica-
tions during the cardiac intervention.
2.3. Surgical technique
Our standard procedure is lung volume reduction surgery
(LVRS) performed bilaterally by video-assisted thoraco-
scopy (VAT), as described previously (2]. Brie¯y, three
11.5 mm trocars are placed in the 7th or 8th ICS and a
5.5-mm trocar in the 4th ICS. A 10-mm, 258 angled thor-
acoscope is used. The resection is aimed at the most
destroyed tissues previously identi®ed by CT scans and
perfusion scintigraphy.
In cases with upper lobe predominance or a diffuse type,
20±30% of the lung volume is resected from the apical
upper lobe in the shape of an inverted `hockey stick'. In
the other cases the resection is aimed at the most destroyed
areas. Two chest tubes on each side are connected to a chest
tube drainage system with Heimlich valves or suction of 10
to 20 cm H2O.
In the patients who underwent CABG or valve replace-
ment combined with LVRS in one operation, LVRS was
performed through the median sternotomy when the patient
was still on bypass. The resection was performed using an
Endolinear cutter (ELC45 Ethicon, Endo-Surgery, Switzer-
land) buttressed with bovine pericardium (Peri-Strips Drye,
Biovascular INC, Saint Paul MN).
2.4. Functional assessment
Lung volumes were measured in a standardized manner
(Sensor Medics 66200 Autobox; Yorba Linda, CA) [7].
Results were expressed as the best values after inhalation
of two puffs of salbutamol. Diffusing capacity for carbon
monoxide was measured by the single breath technique
(66200/Sensor Medics). Reference values were according
to the European community for steel and coal [8].
Exercise capacity was assessed by the 12-min walking
test. The patients walked along the same hospital hallway
without oxygen supplementation encouraged by a techni-
cian [9].
2.5. Statistical analysis
Data analysis was performed by analysis of variance
(ANOVA) with planned comparison using a commercially
available program (STATISTICA for Windows, Version
4.5).
Continuous data are given as mean ^ standard error of
the mean (SEM). Demographic parameters are given as
median and range. P-Values less than 0.05 were considered
signi®cant.
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3. Results
3.1. Lung volume reduction surgery and coronary artery
disease
The results of pulmonary function testing of the nine
CAD patients pre- and postoperatively, at 3 and 6 months
after LVRS are summarized in Table 1. We ®nd an improve-
ment in FEV1 over the ®rst six months following LVRS in
patients who underwent an intervention for CAD in combi-
nation with LVRS (Fig. 1). Furthermore, a reduction of
pulmonary overin¯ation as assessed by the RV/TLC ratio
is observed. Diffusing capacitiy for carbon monoxide
remained unchanged. MRC was signi®cantly lower in
both postoperative follow-up examinations. The outcome
of 12-min walking distance (WD) was slightly improved
but not signi®cantly different from preoperative values.
3.2. Lung volume reduction surgery and valve replacement
All three patients who underwent LVRS in combination
with replacement of the mitral- or aortic valve were treated
outside the prospective LVRS protocol, and therefore did
not meet all criteria to qualify for LVRS according to our
study protocol.
3.2.1. Patient 1
In a 73-year-old female with known COPD and emphy-
sema (FEV1 0.8 l, 42% predicted, TLC 5.45 l, 110%
predicted, RV 3.5L, 165% predicted) a severe aortic valve
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Table 1
Postoperative pulmonary function, exercise capacity (12-min WD (m)), and modi®ed medical council dyspnoe score (MRC) in patients with CAD and before
valve replacement over the ®rst 6 months postoperatively
Pre (n  9) Post (n  6) 3 months (n  5) 6 months (n  6)
FEV1 (l) 0.73 ^ 0.05 0.99 ^ 0.15
a 1.26 ^ 0.16b 1.01 ^ 0.21
FEV1 (%) 25 ^ 1.8 37 ^ 3.9
a 45 ^ 5.1c 38 ^ 5.8a
RV/TLC (%) 0.68 ^ 0.02 0.60 ^ 0.04 0.52 ^ 0.03c 0.56 ^ 0.04b
DLCO (%) 39 ^ 3.2 33 ^ 2.7 38 ^ 4.6 39 ^ 4.9
MRC 3.9 ^ 0.1 0.8 ^ 0.4c 1.2 ^ 0.48c
12-min WD (m) 498 ^ 89 715 ^ 74 664 ^ 46
a P , 0:05:
b P , 0:01:
c P , 0:001 versus preop. values. There were no statistially signi®cant differences between groups at any point in time.
Fig. 1. Respiratory function (FEV1 (L), RV/TLC, DLCO (%)), modi®ed medical research council dyspnoe score (MRC), and exercise capacity (12-min WD
(m)) preoperatively and over the ®rst 6 months postoperatively. In the patients with CAD: pre: n  9; post: n  6; at 3 months: n  5; and at 6 months: n  6,
and patients without CAD (mean ^ SEM).
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stenosis (mean gradient 85 mmHg) was diagnosed. She
suffered from severe dyspnea during normal daily activity
and severe orthopnea at night.
Combined aortic valve replacement and bilateral lung
volume reduction surgery was performed in the same
session via median sternotomy. Postoperatively, severe
pulmonary arterial hypertension developed and was treated
with NO inhalation. The patient was weaned from the
respirator and extubated on the 12th postoperative day.
Antibiotic therapy was required for a unilateral pneumonia
and the patient was leaving the hospital on day 28 post-
operatively.
In the 3 months follow-up examination bronchial obstruc-
tion had decreased as well as pulmonary hyperin¯ation
(FEV1 0.88L, 44% predicted, TLC 4.72 l, 95% predicted,
RV 2.7 l, 128% predicted).
3.2.2. Patient 2
A 67-year-old female with biventricular cardiac insuf®-
ciency (NYHA 3-4), mitral valve stenosis and a mild aortic
valve insuf®ciency was refused in 1994 for mitral valve
replacement because of severe COPD (FEV1 0.84L, 36%
predicted, RV/TLC ratio 0.75, diffusing capacity for carbon
monoxide (DLCO) 39% predicted). The patient was a heavy
smoker for 25 years and was on long-term oxygen therapy
since the beginning of 1996. She suffered from severe
dyspnoea (Medial research council (MRC) dyspnea score:
4), and was very limited in her exercise capacity (12-min
walking distance 540 m).
A combined mitral valve replacement and lung volume
reduction surgery in the same session was planned. After
valve replacement, however, a type A dissection occured.
LVRS was postponed and performed 3 days later which
faciliated successful weaning fom the respirator.
The late postoperative course was further complicated by
urosepsis and the patient was discharged from the hospital
on day 37 postoperatively.
Three months after the operation, dyspnea and exercise
capacity were markedly improved (MRC: 1; 12-min walk-
ing distance 675 m), and lung function showed less obstruc-
tion (FEV1 1.47 l, 67% predicted) and overin¯ation (RV/
TLC 0.54). DLCO revealed a slight improvement to 49%
predicted. Long-term oxygen therapy was no longer neces-
sary. One year after the operation the patient was in good
general condition with FEV1 of 53% predicted, RV/TLC
ratio 0.50, and a 12-min walking distance of 808 m.
3.2.3. Patient 3
A 68-year-old previous heavy smoker suffered from
COPD with alpha-1-antitrypsin de®ciency and severe
bullous emphysema. Furthermore a combined aortic valve
disorder with dominant stenosis (mean gradient 35 mmHg)
was known. Since pulmonary emboli were suspected, the
patient received coumarine since year one. FEV1 was 1.3 l
(47% pred.).
After several hospitalisations for pulmonary decompen-
sation a simultanous valve replacement and LVRS was
planned. Due to accidental perforation of the left ventricle
during the aortic valve replacement, bilateral LVRS was
performed by video-assisted thoracoscopies (VATS) 10
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Fig. 2. Individual pulmonary functional parameters (FEV1 (L), RV/TLC) and exercise capacity (12-min WD (m)) of the three patients before and after valve
replacement in comparison to patients without cardiac disease (mean ^ SEM).
days after the cardiac intervention. At this time point a
pulmonary infection with a multiresistant Pseudomonas
was diagnosed.
After a prolonged weaning period and slow improvement
of the lung function the patient developed severe pneumo-
nia. In the later postoperative course infectious parameters
increased. On the 15th postoperative day the patient died
from multi-organ failure following intestinal infarction.
3.2.4. Morbidity and mortality
One patient in the group with CAD died after develop-
ment of pulmonary edema on day 2 postoperatively and one
patient after valve replacement and LVRS died because of
intestinal infarction on day 14 postoperatively (Table 2).
Postoperative complications after LVRS following a
cardiac intervention include late pneumothorax (n  2),
hematothorax (n  1) and urosepsis (n  1).
3.2.5. Drainage time and hospital stay
In the 12 patients with combined intervention median
drainage time was 11.5 days (range 5±30 days).
The median hospital stay was 15 days (range 10±33
days). In contrast, the two surviving patients after valve
replacement were hospitalised longer, for 28 and 37 days
respectively.
4. Discussion
In this study we retrospectively evaluated the functional
outcome of patients who underwent LVRS in combination
with valve replacement, PTCA, placement of a coronary
stent, or CABG. We found that LVRS can be performed
safely in selected patients who were previously treated for
CAD. The functional outcome in these patients is equal to
LVRS patients without CAD over the ®rst 6 months (Fig. 1).
In addition, we could demonstrate that LVRS enables valve
replacement in selected patients with severe COPD and
emphysema who were previously considered to be inoper-
able.
At the University of Zurich the LVRS program has been
started in early 1994. All patients were included in a
prospective study. Nearly 300 patients have been evaluated
and 124 underwent surgery for emphysema. LVRS at our
institution is mainly performed bilateral in one session by a
video-thoracoscopic approach.
Smoking is the main risk factor for emphysema as well as
for coronary artery disease. Therefore, in these patients
additional risk factors as CAD have to be excluded. Exercise
testing, however, in COPD patients is often not possible due
to severe pulmonary limitation.
In a previous prospective study we could demonstrate that
clinically silent, but relevant CAD is a frequent ®nding in
emphysema patients, otherwise qualifying for LVRS [3].
We found that in 15% of LVRS candidates at least one
relevant coronary artery stenosis (.70% or a 50% stenosis
of the left main coronary artery) is present. After treatment
of CAD with PTCA, stent, or CABG, LVRS can be
performed safely with a low mortality and morbidity similar
to the group of patients without CAD.
When LVRS was performed on a patient while on cardi-
opulmonary bypass, buttressing with bovine pericardial
strips was always used with the aim to prevent bleeding in
the fragile lung tissue of the emphysematous lung. The
improvement in pulmonary function and exercise perfor-
mance was identical in the nine CAD patients as compared
to patients without CAD. These data suggest that a combi-
nation of both interventions is feasible. However, in our
experience it seems to be favourable to select the patients
carefully and to operate preferentially on patients which are
more likely to improve functionally after LVRS (e.g. hetero-
genous emphysema with good target areas) [10].
The rationale for LVRS in patients with valvular heart
disease was different [6]. The combined procedure was
only performed when the patient was severely limited
preoperatively and unable to maintain even everyday aciv-
ities after failure of all conservative treatment modalities.
Basically, the patients were considered inoperable for
valve replacement due to their respiratory insuf®ciency
resulting from severe COPD with emphysema. LVRS
was performed with the aim to improve pulmonary func-
tion to faciliate postoperative weaning from the respirator.
The intraoperative course of two of the described patients
during the cardiac intervention was complicated and LVRS
was postponed and performed 3 and 10 days later under
more stable conditions. Two patients after valve replace-
ment and LVRS showed equal or even improved pulmon-
ary function and exercise performance 3±6 months
postoperatively (Fig. 2).
Since bilateral procedures offer more functional improve-
ment [11], unilateral LVRS is performed only in patients
with severe emphysematous destruction predominantly on
one side. All patients with CAD or valve replacement were
heavy smokers with the exception of one CAD patient with
diffuse unilateral emphysema. A bilateral approach was
favoured to achive maximal respiratory bene®t in these
high risk patients. A unilateral approach was not due to
intraoperative complications in our patients.
Postoperative pulmonary improvement in patients who
underwent CABG or valve replacement are even more
impressive since it has been demonstrated in previous
studies that in patients with normal preoperative respiratory
function who undergo cardiac surgery (CABG or valve
replacement) FEV1 and FVC decrease postoperatively by
at least 10% over several months [12].
Our experience with surgical treatment for empysema
and cardiac valve disorder demonstrates that combined
interventions can be performed successfully in selected
patients. The morbidity and mortality are acceptable.
However, this surgical concept can only be recommended
for centers with a large experience in postoperative manage-
ment of patients with severe emphysema.
R.A. Schmid et al. / European Journal of Cardio-thoracic Surgery 15 (1999) 585±591590
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Appendix A. Conference discussion
Dr H. Toomes (Gerlingen, Germany): I want to ask about your strategy
once more. Do you always plan to make the operations, lung and cardiac,
simultaneously? Or why don't you do it simultaneously?
Dr Schmid: I think this is risk stratifying. In the valve patient, it was
always planned to perform LVRS through the median sternotomy in the
same session at the end of the procedure when the patient was still on
bypass. We used buttressing of the staple line in all cases to prevent
parenchymal haemorrhage, and we did not have any bleeding problems.
On two occasions, during the cardiac intervention severe intraoperative
complications occurred, which prolonged bypass time, and we had to
delay the lung volume reduction procedure. One patient we tried to wean
from the respirator, but it was impossible. Lung volume reduction surgery
was performed and 10 days later we could extubate the patient. This case
was published in the Journal of Thoracic and Cardiovascular Surgery in
1998.
Dr F. Venuta (Rome, Italy): I did not understand which procedures you
did ®rst in the series of patients that you treated at the same time with
cardiac procedure and lung volume reduction. I mean, did you do the
lung volume reduction before putting the patient on bypass, or after?
Dr Schimd: After the cardiac operation, but still on bypass.
Dr Venuta: So you reversed heparin and then you did the lung volume
reduction?
Dr Schmid: No, we performed LVRS. When the patient was, as I just
mentioned, still on bypass.
Dr T. Dosios (Athens, Greece): I understood that all your patients had
coronary arteriogram done before the operation. Is it correct?
Dr Schmid: In the very initial experience of lung volume reduction
surgery, we performed it in all patients. Evaluating our data, we found
that it is only indicated when you have clinical suspicion, or certain risk
factors, except smoking of course. In general, we do now perform LVRS
without coronary angiography.
Dr P. Baptista (Carnaxide, Portugal): From what I understood in the
beginning, you did coronary angiograms in all patients proposed to lung
reduction. And then you said you only did it when there was suspicion of
cardiac pathology. Why not do just stress efforts in every patient, which is
something we can do very easily?
Dr Schmid: The emphysema patients usually can not perform ergome-
try because of their pulmonary limitation. Therefore, if there is any clinical
suspicion for coronary heart disease we liberally perform angiography.
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